# US 2016/0257947 A9 · Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257947 A9
- Document ID: US20160257947A9
- Status: Published application
- Kind: A9
- Application number: 14/017,885
- Filed: 2013-09-04
- Published: 2016-09-08
- Earliest claimed: 2004-02-13
- Assignees: IBC Pharmaceuticals, Inc.; Immunomedics, Inc.
- Applicants: Ibc Pharmaceuticals, Inc.; Immunomedics, Inc.
- Inventors: Chien-Hsing Chang; David M. Goldenberg; Edmund A. Rossi
- Web page: https://patentgrep.com/patent/US20160257947A9

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001113: {CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2}
- A61K 39/001114: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
- A61K 39/001124: {CD20}
- A61K 39/00117: {Mucins, e.g. MUC-1}
- A61K 39/001182: {Carcinoembryonic antigen [CEA]}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 47/6897: {Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/2887: {against CD20}
- C07K 16/30: from tumour cells
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 207/11011: cAMP-dependent protein kinase (2.7.11.11)
- C12Y 301/27: Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/6056: {Antibodies}
- A61K 2039/625: {binding through the biotin-streptavidin system or similar}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.

## Claims

### Claim 1

A complex comprising:
a) a first fusion protein comprising a toxin attached to a DDD (dimerization and docking domain) moiety from human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein the toxin is selected from the group consisting of ranpirnase (Rap), saporin, diptheria toxin, gelonin, Pseudomonas exotoxin; and
b) a second fusion protein comprising an antibody or antigen binding antibody fragment attached to an AD (anchoring domain) moiety from an AKAP protein, wherein the antibody or antibody fragment is selected from the group consisting of hR1 (anti-IGF-1R), hPAM4 (anti-mucin), hA20 (anti-CD20), hLL1 (anti-CD74), hLL2 (anti-CD22), hL243 (anti-HLA-DR), hMN-14 (anti-CEA), hMN-15 (anti-CEA) and hRS7 (anti-EGP-1);
wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex.

### Claim 2 (depends on 1)

The complex according to claim 1, wherein the complex comprises four copies of the toxin.

### Claim 3 (depends on 1)

The complex of claim 1, wherein the antibody or antibody fragment is selected from the group consisting of an IgG, a F(ab′)2, a F(ab)2, a Fab′, a Fab, a Fv, a sFv, a scFv and a dAb.

### Claim 4 (depends on 1)

The complex according to claim 1, wherein the antibody or antibody fragment is selected from the group consisting of hRS7 (anti-EGP-1), hLL1 (anti-CD74), hLL2 (anti-CD22) and hA20 (anti-CD20).

### Claim 5

A complex comprising:
a) a first fusion protein comprising a toxin attached to a DDD (dimerization and docking domain) moiety from human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein the toxin is ranpirnase (Rap); and
b) a second fusion protein comprising an antibody or antigen binding antibody fragment attached to an AD (anchoring domain) moiety from an AKAP protein, wherein the antibody or antibody fragment is selected from the group consisting of hR1 (anti-IGF-1R), hPAM4 (anti-mucin), hA20 (anti-CD20), hA19 (anti-CD19), hIMMU31 (anti-AFP), hLL1 (anti-CD74), hLL2 (anti-CD22), hMu-9 (anti-CSAp), hL243 (anti-HLA-DR), hMN-14 (anti-CEACAM5), hMN-15 (anti-CEACAM6), hRS7 (anti-EGP-1) and hMN-3 (anti-CEACAM6);
wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex.

### Claim 6 (depends on 5)

The complex according to claim 5, wherein the complex comprises four copies of the toxin.

### Claim 7 (depends on 5)

The complex of claim 5, wherein the antibody or antibody fragment is selected from the group consisting of an IgG, a F(ab′)2, a F(ab)2, a Fab′, a Fab, a Fv, a sFv, a scFv and a dAb.

### Claim 8 (depends on 5)

The complex according to claim 5, wherein the antibody or antibody fragment is selected from the group consisting of hRS7 (anti-EGP-1), hLL1 (anti-CD74), hLL2 (anti-CD22) and hA20 (anti-CD20).
